Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early‐stage breast cancer patients who received trastuzumab: Evidence from a real‐world study with long‐term follow‐up
Abstract Background Hormone receptor‐positive (HR+)/human epidermal growth factor receptor 2‐positive (HER2+) breast cancer exhibits considerable heterogeneity, and it is of great interest whether patients with premenopausal HR+/HER2+ breast cancer treated with trastuzumab can benefit from ovarian f...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-02-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.15211 |
| _version_ | 1827344900808507392 |
|---|---|
| author | Jie Ju Song‐Lin Gao Jia‐Yu Wang Die Sang Yi‐Kun Kang Xue Wang Jian Yue You Shuai Yi‐Xin Qi Peng Yuan |
| author_facet | Jie Ju Song‐Lin Gao Jia‐Yu Wang Die Sang Yi‐Kun Kang Xue Wang Jian Yue You Shuai Yi‐Xin Qi Peng Yuan |
| author_sort | Jie Ju |
| collection | DOAJ |
| description | Abstract Background Hormone receptor‐positive (HR+)/human epidermal growth factor receptor 2‐positive (HER2+) breast cancer exhibits considerable heterogeneity, and it is of great interest whether patients with premenopausal HR+/HER2+ breast cancer treated with trastuzumab can benefit from ovarian function suppression (OFS) therapy similarly to HR+/HER2‐ breast cancer. Here, we conducted a real‐world study in this population to identify both who would derive substantial benefits from the addition of OFS and clinicopathological factors with potential prognostic value. Methods Multicenter data from 253 premenopausal patients with HR+/HER2+ early‐stage breast cancer who received trastuzumab from October 2009 to October 2018 were retrospectively included. The Kaplan–Meier method was used for survival analysis, while the log‐rank test was used to compare the survival rates. Univariate and multifactor Cox regression analyses were performed to analyze the independent risk factors affecting invasive disease‐free survival (IDFS). Results After a median follow‐up of 98.50 months, compared with tamoxifen/toremifene alone, tamoxifen/toremifene/aromatase inhibitors plus OFS demonstrated significant benefits in the overall study population (HR = 0.289, 95% CI: 0.100–0.835, p = 0.022, 8‐year IDFS rate: 90.78% vs. 95.54%), especially in the lymph node‐positive subgroup and age ≤40 years subgroup. Age ≤40 years, histological grade >2, lymph node involvement, PR ≤50%, and tamoxifen alone were independent prognostic factors. Conclusions For premenopausal HR+ breast cancer patients, HER2 positivity alone is an indication for the addition of OFS in adjuvant endocrine therapy. Age, histological grade, lymph node status, the expression of PR, and OFS treatment were independent prognostic factors in this population. |
| first_indexed | 2024-03-07T22:56:16Z |
| format | Article |
| id | doaj.art-7102535824db4279a226792825f0e5fc |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-03-07T22:56:16Z |
| publishDate | 2024-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-7102535824db4279a226792825f0e5fc2024-02-23T02:10:40ZengWileyThoracic Cancer1759-77061759-77142024-02-0115643944710.1111/1759-7714.15211Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early‐stage breast cancer patients who received trastuzumab: Evidence from a real‐world study with long‐term follow‐upJie Ju0Song‐Lin Gao1Jia‐Yu Wang2Die Sang3Yi‐Kun Kang4Xue Wang5Jian Yue6You Shuai7Yi‐Xin Qi8Peng Yuan9Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), The VIPII Gastrointestinal Cancer Division of Medical Department Peking University Cancer Hospital and Institute Beijing ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology Beijing Sanhuan Cancer Hospital Beijing ChinaDepartment of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine Chinese Academy of Medical Sciences Beijing ChinaDepartment of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaDepartment of Breast Center The Fourth Hospital of Hebei Medical University Shi Jiazhuang ChinaDepartment of VIP Medical Services, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing ChinaAbstract Background Hormone receptor‐positive (HR+)/human epidermal growth factor receptor 2‐positive (HER2+) breast cancer exhibits considerable heterogeneity, and it is of great interest whether patients with premenopausal HR+/HER2+ breast cancer treated with trastuzumab can benefit from ovarian function suppression (OFS) therapy similarly to HR+/HER2‐ breast cancer. Here, we conducted a real‐world study in this population to identify both who would derive substantial benefits from the addition of OFS and clinicopathological factors with potential prognostic value. Methods Multicenter data from 253 premenopausal patients with HR+/HER2+ early‐stage breast cancer who received trastuzumab from October 2009 to October 2018 were retrospectively included. The Kaplan–Meier method was used for survival analysis, while the log‐rank test was used to compare the survival rates. Univariate and multifactor Cox regression analyses were performed to analyze the independent risk factors affecting invasive disease‐free survival (IDFS). Results After a median follow‐up of 98.50 months, compared with tamoxifen/toremifene alone, tamoxifen/toremifene/aromatase inhibitors plus OFS demonstrated significant benefits in the overall study population (HR = 0.289, 95% CI: 0.100–0.835, p = 0.022, 8‐year IDFS rate: 90.78% vs. 95.54%), especially in the lymph node‐positive subgroup and age ≤40 years subgroup. Age ≤40 years, histological grade >2, lymph node involvement, PR ≤50%, and tamoxifen alone were independent prognostic factors. Conclusions For premenopausal HR+ breast cancer patients, HER2 positivity alone is an indication for the addition of OFS in adjuvant endocrine therapy. Age, histological grade, lymph node status, the expression of PR, and OFS treatment were independent prognostic factors in this population.https://doi.org/10.1111/1759-7714.15211breast cancerhormone receptorhuman epidermal growth factor receptor 2ovarian function suppressiontrastuzumab |
| spellingShingle | Jie Ju Song‐Lin Gao Jia‐Yu Wang Die Sang Yi‐Kun Kang Xue Wang Jian Yue You Shuai Yi‐Xin Qi Peng Yuan Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early‐stage breast cancer patients who received trastuzumab: Evidence from a real‐world study with long‐term follow‐up Thoracic Cancer breast cancer hormone receptor human epidermal growth factor receptor 2 ovarian function suppression trastuzumab |
| title | Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early‐stage breast cancer patients who received trastuzumab: Evidence from a real‐world study with long‐term follow‐up |
| title_full | Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early‐stage breast cancer patients who received trastuzumab: Evidence from a real‐world study with long‐term follow‐up |
| title_fullStr | Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early‐stage breast cancer patients who received trastuzumab: Evidence from a real‐world study with long‐term follow‐up |
| title_full_unstemmed | Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early‐stage breast cancer patients who received trastuzumab: Evidence from a real‐world study with long‐term follow‐up |
| title_short | Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early‐stage breast cancer patients who received trastuzumab: Evidence from a real‐world study with long‐term follow‐up |
| title_sort | prognostic factors and benefit populations of ovarian function suppression in premenopausal hr her2 early stage breast cancer patients who received trastuzumab evidence from a real world study with long term follow up |
| topic | breast cancer hormone receptor human epidermal growth factor receptor 2 ovarian function suppression trastuzumab |
| url | https://doi.org/10.1111/1759-7714.15211 |
| work_keys_str_mv | AT jieju prognosticfactorsandbenefitpopulationsofovarianfunctionsuppressioninpremenopausalhrher2earlystagebreastcancerpatientswhoreceivedtrastuzumabevidencefromarealworldstudywithlongtermfollowup AT songlingao prognosticfactorsandbenefitpopulationsofovarianfunctionsuppressioninpremenopausalhrher2earlystagebreastcancerpatientswhoreceivedtrastuzumabevidencefromarealworldstudywithlongtermfollowup AT jiayuwang prognosticfactorsandbenefitpopulationsofovarianfunctionsuppressioninpremenopausalhrher2earlystagebreastcancerpatientswhoreceivedtrastuzumabevidencefromarealworldstudywithlongtermfollowup AT diesang prognosticfactorsandbenefitpopulationsofovarianfunctionsuppressioninpremenopausalhrher2earlystagebreastcancerpatientswhoreceivedtrastuzumabevidencefromarealworldstudywithlongtermfollowup AT yikunkang prognosticfactorsandbenefitpopulationsofovarianfunctionsuppressioninpremenopausalhrher2earlystagebreastcancerpatientswhoreceivedtrastuzumabevidencefromarealworldstudywithlongtermfollowup AT xuewang prognosticfactorsandbenefitpopulationsofovarianfunctionsuppressioninpremenopausalhrher2earlystagebreastcancerpatientswhoreceivedtrastuzumabevidencefromarealworldstudywithlongtermfollowup AT jianyue prognosticfactorsandbenefitpopulationsofovarianfunctionsuppressioninpremenopausalhrher2earlystagebreastcancerpatientswhoreceivedtrastuzumabevidencefromarealworldstudywithlongtermfollowup AT youshuai prognosticfactorsandbenefitpopulationsofovarianfunctionsuppressioninpremenopausalhrher2earlystagebreastcancerpatientswhoreceivedtrastuzumabevidencefromarealworldstudywithlongtermfollowup AT yixinqi prognosticfactorsandbenefitpopulationsofovarianfunctionsuppressioninpremenopausalhrher2earlystagebreastcancerpatientswhoreceivedtrastuzumabevidencefromarealworldstudywithlongtermfollowup AT pengyuan prognosticfactorsandbenefitpopulationsofovarianfunctionsuppressioninpremenopausalhrher2earlystagebreastcancerpatientswhoreceivedtrastuzumabevidencefromarealworldstudywithlongtermfollowup |